Fabio Petrocca, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MD, University of Rome



Diversity, Equity, Inclusion and Accessibility

I am part of a dedicated team of healthcare professionals, researchers, students and staff from different countries and various regions of the U.S. The culture of our Section is defined by the unique perspectives that we each bring with us. As both a large academic medical center and safety-net hospital serving the communities of Boston and its surroundings, our trainees engage in cutting edge research and gain real-world clinical experience by caring for local underserved populations. Our multilingual team is committed to promoting cultural competency, equity and inclusion in science, medicine and healthcare. We strive to maintain a workforce that is as diverse as the communities we serve, and aim to create a safe space for our members to learn, grow and succeed in their life goals. Acknowledging that we all have a role to play, I am dedicated to welcoming and celebrating individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation, veteran status, and national origin.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023 Sep; 29(9):2286-2294.View Related Profiles. PMID: 37592106; PMCID: PMC10504071; DOI: 10.1038/s41591-023-02496-0;
     
  2. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716.View Related Profiles. PMID: 33626253
     
  3. Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep. 2021 Feb 19; 15(1):90. PMID: 33608053; PMCID: PMC7894235; DOI: 10.1186/s13256-020-02598-0;
     
  4. Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.View Related Profiles. PMID: 33558511; PMCID: PMC7870932; DOI: 10.1038/s41467-021-21177-5;
     
  5. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737.View Related Profiles. PMID: 31042825; PMCID: PMC8202968; DOI: 10.1056/NEJMoa1817226;
     
  6. Chan S, Sridhar P, Kirchner R, Lock YJ, Herbert Z, Buonamici S, Smith P, Lieberman J, Petrocca F. Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Mol Cancer Ther. 2017 Dec; 16(12):2849-2861.View Related Profiles. PMID: 28878028; PMCID: PMC5997774; DOI: 10.1158/1535-7163.MCT-17-0461;
     
  7. Sridhar P, Petrocca F. Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy. Cancers (Basel). 2017 Jul 18; 9(7). PMID: 28718815; PMCID: PMC5532628; DOI: 10.3390/cancers9070092;
     
  8. Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, Ince TA. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2017 Mar 23; 36(12):1707-1720. PMID: 27694895; PMCID: PMC5364039; DOI: 10.1038/onc.2016.337;
     
  9. De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Hoyos JM, Forzati F, Croce CM, Fusco A. Regulation of microRNA expression by HMGA1 proteins. Oncogene. 2016 11 03; 35(44):5817-5818. PMID: 27399337; DOI: 10.1038/onc.2016.136;
     
  10. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2016 09 29; 35(39):5214. PMID: 27345412; DOI: 10.1038/onc.2016.139;
     
Showing 10 of 30 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 30 publications over 12 distinct years, with a maximum of 5 publications in 2007 and 2008

YearPublications
20062
20075
20085
20094
20101
20131
20152
20163
20172
20191
20213
20231

2014-2017 National Cancer Institute: NCI K22 Transitional Career Award

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

820 Harrison Ave, FGH 2
Boston MA 02118
Google Map


Petrocca's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department